Brainsway’s market value has already surpassed 600 million dollars. The market seems to highly value a profitably growing TMS company, but there are still less valued options available for interested buyers.
Brainsway also released a press release yesterday stating that in the US, TMS treatment administered by nurse practitioners is increasingly being accepted for insurance coverage. This is, of course, a great thing for all TMS companies, but a particularly positive development for Nexstim. If you have had the chance to see the navigation of Nexstim’s NBS 6 system, it has become quite clear that even a child could find the correct treatment spot (with the possible exception of the first session of the treatment cycle) to ensure the treatment is correctly targeted and repeatable.